Cardioprotective effect of zofenopril, thymoquinone and their combination in cyclophosphamide-induced cardiotoxicity in rats.
AI Summary
Key Findings
Abstract
BackgroundCyclophosphamide (Cyp) is associated with various organ toxicities. The study aimed to investigate the efficacy of zofenopril (Zf), thymoquinone (Thym), and their combination in Cyp-induced cardiotoxicity.MethodologyThirty rats were divided into five groups of six rats each. They received the following treatment orally for 19 days: Control (Con) and Cyp groups: normal saline. Zf: Zf 15 mg/kg, Thym: Thym 80 mg/kg, and Zf + Thym: a combination of both. A single dose of Cyp 200 mg/kg intraperitoneally (IP) was given on day 17 of the experiment to all the groups except the Con. Cardiac, inflammatory, and apoptotic biomarkers, including troponin T, lactate dehydrogenase (LDH), CK-MB, hs-CRP, nuclear factor kappa B (NF-κB), caspase-3, and total antioxidant capacity (TAC), along with lipid profile and histopathological lesions, were assessed.ResultsCyp resulted in cardiotoxicity as manifested by a significant increase in troponin T, CK-MB, caspase-3, hs-CRP, suppression of TAC level, and marked histopathological alterations in cardiac tissues. Zf, Thym, and their combination significantly reduced CK-MB levels. NF-κB level was significantly decreased by Thym, while the combination of Zf and Thym significantly elevated TAC. hs-CRP was significantly reduced only by Zf. Caspase-3 were significantly lowered by both Zf and Thym individually, as well as by their combination.ConclusionZf and Thym provided cardioprotection against Cyp-induced cardiotoxicity through distinct mechanisms. Zf exhibited anti-inflammatory effects, evidenced by a significant reduction in hs-CRP, along with anti-apoptotic activity. Thym significantly suppressed NF-κB expression. Their combination enhanced antioxidant capacity, however, no superiority over individual treatments was observed concerning their other actions.
Affiliation
Sakar Karem Abdulla
External References
- PubMed ID:
- 40884746
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.